Ryan Harris, MD
Dermatology · Meridian, IDNPI 1952628745
Payments from drug & device makers
Across 308 payments — averaging $2394.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$194K
- Pfizer$162K
- E.r. Squibb & Sons, L.L.C.$148K
- Endo Pharmaceuticals Inc.$136K
- AbbVie$63K
- VYNE Pharmaceuticals Inc.$15K
- plus $20K from 23 others
Across 10 payments — averaging $1940.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$19K
What the payments were for
- Consulting fees$9002%
- Speaking & faculty fees$42,62774%
- Travel & lodging$9,68817%
- Food & beverage$4,3187%
- Education$3701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 14 | $193,567 |
| Pfizer | 79 | $161,646 |
| E.r. Squibb & Sons, L.L.C. | 39 | $148,052 |
| Endo Pharmaceuticals Inc. | 24 | $136,131 |
| AbbVie | 39 | $62,797 |
| VYNE Pharmaceuticals Inc. | 19 | $15,105 |
| Incyte Corporation | 29 | $7,128 |
| Boehringer Ingelheim | 3 | $5,745 |
| Amgen | 8 | $4,142 |
| Dr.reddy's Laboratories,inc. | 2 | $2,000 |
| Johnson & Johnson | 12 | $425 |
| Sun Pharmaceutical Industries Inc. | 6 | $193 |
| Lilly USA, LLC | 5 | $110 |
| Novartis | 3 | $67 |
| Arcutis Biotherapeutics, Inc. | 3 | $56 |
| Dermavant Sciences, Inc. | 3 | $53 |
| UCB, Inc. | 3 | $44 |
| Merz North America, Inc. | 2 | $43 |
| Galderma Laboratories, L.p. | 2 | $39 |
| Sanofi | 2 | $38 |
| Stemline Therapeutics Inc. | 1 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| LEO Pharma Inc. | 2 | $32 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $29 |
| Mayne Pharma Commercial LLC | 1 | $21 |
| AstraZeneca | 1 | $20 |
| Urgo Medical North America, LLC | 1 | $18 |
| Botanix SB Inc | 1 | $17 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$737,605 in reported general payments places this provider in the 95th percentile of 52 dermatology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 17 | $114,049 |
| Clobetasol Propionate | 75 | $4,041 |
| Fluocinonide | 46 | $1,407 |
| Ketoconazole | 105 | $1,361 |
| Doxycycline Hyclate | 17 | $594 |
| Triamcinolone Acetonide | 71 | $463 |
| CiclopiroxCiclopirox Olamine | 13 | $127 |
| Terbinafine Hcl | 15 | $95 |
| Hydrocortisone | 13 | $76 |
| Ciclopirox | 11 | $76 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Meridian
- Mark SchwendimanMeridian$9K
- Kelsey FerrellMeridian$6K
- Randall BurrMeridian$5K
- Benjamin PerryMeridian$4K
- Richard ThomasMeridian$4K
- Gregory WellsMeridian$3K
- Whitney VinsonMeridian$3K
- Alan PittMeridian$2K
- Emily BoozalisMeridian$2K
- Ryan WellsMeridian$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.